← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Glytr Therapeutics, Inc.
San Carlos, CA
$3,556,672
Total funding
4
Grants
Funding over time
peak $1.5M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,556,672 · 4
By mechanism
R42$2,857,880 · 2
R41$698,792 · 2
Investigators at Glytr Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy$1,085,460
R42 · FY2025 · CA
Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy$908,910
R42 · FY2024 · CA
Maximizing GlyTR pan-cancer immunotherapy by enhancing target density$463,510
R42 · FY2025 · CA
Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy$400,000
R42 · FY2023 · CA
Cancer Immunotherapy Targeting Tn Antigen$398,178
R41 · FY2021 · CA
O-Glycan-dependent Immunotherapy for Cancer$298,530
R41 · FY2018 · CA
O-Glycan-dependent Immunotherapy for Cancer$2,084
R41 · FY2019 · CA